[Date of Approval] February 4, 2008
[Date of Revision] October 13, 2008
[Date of Revision] March 22, 2010
[Date of Revision] March 20, 2017

Package Insert for Jiuweizhenxin Granules

Please carefully read the package insert and use under the guidance of a physician

[Drug Name]

Generic name: Jiuweizhenxin Granules

Chinese pinyin: Jiuwei Zhenxin Keli

[Ingredients] Ginseng (rhigome-removed), wild jujube seed, schisandra, poria, polygala tenuifolia, corydalis tuber, asparagus cochinchinensis, prepared rehmannia root, cinnamon.

[Description] The product is brown particles, slightly fragrant, with a bitter taste.

[Indications] Intended for nourishing the heart and the spleen, replenishing qi and soothing the nerves. The product is intended for generalized anxiety disorder with the syndrome of deficiency of both heart and spleen, including symptoms such as oversensitivity, excessive anxiety and worries, agrypnia or dreaminess, palpitations, inappetence, fatigue, wooziness, sweating, frequent sighs, yellow complexion, pale tongue and thin white fur, small and wiry pulse or deep thready pulse.

[Strength] Each bag contains 6 g.

[Dosage and Administration] Administered with warm boiled water, 1 bag each in the morning, at noon and in the evening, 3 times a day.

[Adverse Reactions] Occasionally dry mouth, hazy vision, increased constipation, nausea and vomiting, diarrhea, inappetence or anorexia, abdominal distension, bitter mouth, gastric pain, somnolence, agrypnia, tremor, headache, wooziness, lipothymia, electrocardiogram abnormal, palpitations, tachycardia, ALT increased, white blood cells decreased, and menstrual disorders.

[Contraindications] Not clear.

[Precautions] Those with abnormal cardiac function or liver function and decreased white blood cells should use the product with caution.

[Clinical Trials] The product was approved for clinical trials by the former State Food and Drug Administration in January 2002, and clinical trials were carried out from July 2002 to

August 2004. All clinical trials adopted parallel-controlled, randomized, double-blind, double-dummy, multicenter clinical trial design method to observe the efficacy and safety of Jiuweizhenxin Granules in the treatment of generalized anxiety disorder with the syndrome of deficiency of both heart and spleen, with buspirone hydrochloride tablets as the reference drug. The cases included were patients with generalized anxiety disorder whose TCM syndrome differentiation was syndrome of deficiency of both heart and spleen. A total of 227 cases were observed in Phase II clinical trials, including 114 cases in the Jiuweizhenxin Granules group and 113 cases in the control group. A total of 447 cases were observed in Phase III clinical trials, including 336 cases in the Jiuweizhenxin Granules group and 111 cases in the control group. Usage: Both groups took the drug orally. Jiuweizhenxin Granules group: 1 bag of Jiuweizhenxin Granules, 3 times a day, as well as buspirone hydrochloride tablets mimic, 1 tablet each time, 3 times a day; control group: buspirone hydrochloride tablets, 1 tablet each time, 3 times a day, as well as Jiuweizhenxin Granules mimic, 1 bag each time, 3 times a day. Both groups were observed for 4 weeks. The primary efficacy observational indicators were Hamilton Anxiety Scale (HAMA) total score, HAMA factor (including mental anxiety factor and physical anxiety factor) score and efficacy classification evaluation, TCM syndrome total score and efficacy classification evaluation. The trial results showed that in Phase II clinical trials, compared with before treatment, the changes in HAMA total score, HAMA mental anxiety factor score, HAMA physical anxiety factor score, and TCM syndrome total score were improved after treatment in the Jiuweizhenxin Granules group, and the differences were statistically significant ($P<0.01$). In the buspirone hydrochloride tablets group, similar results were obtained on the improvement of HAMA total score, HAMA mental anxiety factor score, HAMA physical anxiety factor score, and TCM syndrome total score. Inter-group comparisons showed no statistically significant differences. The efficacy results of Phase III clinical trials were the same as those of Phase II clinical trials. Patients in the Jiuweizhenxin Granules group received hematology, urinalysis, fecal analysis, liver (ALT), kidney (BUN, Cr) functions and electrocardiography. After clinical observation, occasional related adverse events

included dry mouth, hazy vision, increased constipation, nausea and vomiting, diarrhea, inappetence or anorexia, abdominal distension, bitter mouth, gastric pain, somnolence, agrypnia, tremor, headache, wooziness, lipothymia, electrocardiogram abnormal, palpitations, tachycardia, increased ALT, decreased white blood cells, and menstrual disorder.

[Pharmacology and Toxicology] Animal test results have suggested that this product could increase the staying time of anxious mice in the open box and shorten the staying time in the dark box; increase the number of water drinking and the number of electric shocks when anxious rats drink, and increase the number of anxious rats entering the elevated plus maze to open their arms and the percentage of staying time with arms open; reduce the content of DA and NE in the brain tissue of anxious rats, yet with no significant effect on the content of 5-HT; reduce the autonomous activity of mice and prolong the sleep time of mice induced by pentobarbital sodium, increase the number of mice falling asleep at the subthreshold hypnotic dose of pentobarbital sodium; extend the latency of pentylenetetrazole-induced convulsions in mice, and reduce the mortality of pentetrazol-induced convulsions in mice; extend the post-decollation gasping maintenance time of mice; and reverse the increase in blood pressure of cats caused by NE to varying degrees.

[Storage] Tightly sealed.

[Package] Packed in aluminum-plastic composite film bag, 6 g per bag.

[Shelf Life] 36 months.

[Executive Standard] YBZ00112008

[Approval Number] NMPA License No. Z20080008

[Manufacturer]

Enterprise name: Beijing Beilu Pharmaceutical Co., Ltd.

Production address: Industrial Development Zone, Miyun District, Beijing

Postal code: 101500

Tel: (010) 62622266

Fax: (010) 82626933

Website: http://www.beilu.com.cn